Pharmanomics copertina

Pharmanomics

How Big Pharma Destroys Global Health

Anteprima
Iscriviti ora Iscriviti ora
Offerta valida fino alle 23.59 del 29 gennaio 2026.
Dopo 30 giorni (60 per i membri Prime), 9,99 €/mese. Puoi cancellare ogni mese
Risparmio di più del 90% nei primi 3 mesi.
Ascolto illimitato della nostra selezione in continua crescita di migliaia di audiolibri, podcast e Audible Original.
Nessun impegno. Puoi cancellare ogni mese.
Disponibile su ogni dispositivo, anche senza connessione.
Ascolta senza limiti migliaia di audiolibri, podcast e serie originali
Disponibile su ogni dispositivo, anche senza connessione
9,99 € al mese. Puoi cancellare ogni mese.

Pharmanomics

Di: Nick Dearden
Letto da: Gareth Richards
Iscriviti ora Iscriviti ora

3 mesi a soli 0,99 €/mese, dopodiché 9,99 €/mese. Possibilità di disdire ogni mese. L'offerta termina il 29 gennaio 2026 alle 23:59.

Dopo 30 giorni (60 per i membri Prime), 9,99 €/mese. Cancella quando vuoi.

Acquista ora a 15,95 €

Acquista ora a 15,95 €

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

In Pharmanomics, investigative journalist Nick Dearden digs down into the way we produce our medicines and finds that Big Pharma is failing us, with catastrophic consequences.

Big Pharma is more interested in profit than health. This was made clear as governments rushed to produce vaccines during the Covid pandemic. Behind the much-trumpeted scientific breakthroughs, major companies found new ways of gouging billions from governments in the West while abandoning the Global South. But this is only the latest episode in a long history of financializing medicine—from Purdue's rapacious marketing of highly addictive OxyContin through Martin Shkreli's hiking the price of a lifesaving drug to the 4.5 million South Africans needlessly deprived of HIV/AIDS medication.

Since the 1990s, Big Pharma has gone out of its way to protect its property through the patent system. As a result, the business has focused not on researching new medicines but on building monopolies. This system has helped restructure our economy away from invention and production in order to benefit financial markets. It has fundamentally reshaped the relationship between richer and poorer countries, as the access to new medicines and the permission to manufacture them is ruthlessly policed. In response, Dearden offers a pathway to a fairer, safer system for all.

©2023 Nick Dearden (P)2023 Tantor
Medicina e industria sanitaria Politica e governo Politica pubblica
Ancora nessuna recensione